MSB 2.17% $1.13 mesoblast limited

There you go... the reason for the Ryoncil BLA Resubmission...

  1. 12,429 Posts.
    lightbulb Created with Sketch. 3371
    There you go... the reason for the Ryoncil BLA Resubmission delay

    They were waiting for this - I feel better now biggrin.png

    I'll see you guys at the AGM - I'll be in a blue top, so come over and say hi if you are in the room!


    Key Points:
    • Long-term survival evident through 4 years in children treated with remestemcel-L in Phase 3trial MSB-GVHD001
    • Overall survival at 2 years was 51% in remestemcel-L treated children and 25-38% in recentlypublished studies of children or adults with SR-aGVHD who received best available therapy(BAT) or the only approved agent in adults1-4
    • These results reaffirm the potential significance of remestemcel-L as a life-saving therapy forchildren with SR-aGVHD
    • These long-term survival outcomes are a key component of the Biologics License Application(BLA) resubmission to the United States Food and Drug Administration (FDA)
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
-0.025(2.17%)
Mkt cap ! $1.284B
Open High Low Value Volume
$1.15 $1.16 $1.11 $7.363M 6.488M

Buyers (Bids)

No. Vol. Price($)
5 94863 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 5000 2
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.